• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Blood Coagulants Market Size

    ID: MRFR/Pharma/2027-CR
    53 Pages
    Kinjoll Dey
    July 2017

    Middle East & Africa Blood Coagulants Market Research Report Information, By Types (Coagulation Factor, others), Indication (Haemophilia, Surgery, other Bleeding Disorders) -Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Blood Coagulants Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Blood Coagulants Size

    Blood Coagulants Market Growth Projections and Opportunities

    The market for Blood Coagulants is appreciably influenced by the growing occurrence of hemostatic problems, which include hemophilia and von Willebrand ailment. The increasing occurrence of those conditions globally contributes to the developing demand for powerful blood coagulation treatment options. The demand for Blood Coagulants is driven by the widespread use of those sellers in surgical methods and trauma cases. Blood Coagulants play an essential function in stopping immoderate bleeding for the duration of surgical procedures and handling bleeding associated with annoying injuries, contributing to their large utility in healthcare settings. The worldwide demographic shift in the direction of a growing old population is a key component driving the Blood Coagulants market. Older individuals are extra at risk of hemostatic problems and might require blood coagulation aid, leading to expanded demand for these treatments as the elderly population continues to develop. Cardiovascular diseases frequently require anticoagulant therapy to prevent blood clots and related complications. The growing occurrence of cardiovascular sicknesses globally contributes drastically to the demand for Blood Coagulants, particularly anticoagulant medicines. Blood coagulants are increasingly being explored for new warning signs beyond conventional uses. Research and development efforts are cognizant of expanding the therapeutic packages of Blood Coagulants to cope with a wider variety of situations, similarly using market increase. The evolving healthcare landscape emphasizes patient-centric approaches, influencing the improvement of Blood Coagulants. Therapies that offer stepped-forward comfort, reduced aspect effects, and stronger affected person adherence contribute to the market's evolution, aligning with the wider goals of affected person satisfaction and consequences. Collaborations and partnerships between pharmaceutical businesses, study establishments, and healthcare agencies play a pivotal role in advancing Blood Coagulants. These partnerships foster research, improvement, and the commercialization of revolutionary coagulation treatments, shaping the aggressive panorama. Stringent regulatory requirements and help for the development of safe and effective Blood Coagulants influence market dynamics. Regulatory approvals and compliance with established hints are vital for gaining acceptance as true with healthcare professionals and making sure of the successful introduction of recent coagulation merchandise to the market.

    Blood Coagulants Market Size Graph

    Market Summary

    The Middle East and Africa Blood Coagulants Market is projected to experience substantial growth from 1250 USD Million in 2024 to 2750 USD Million by 2035.

    Key Market Trends & Highlights

    Middle East & Africa Blood Coagulants Key Trends and Highlights

    • The market is expected to grow at a CAGR of 7.43% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 2750 USD Million, indicating robust demand.
    • In 2024, the market is valued at 1250 USD Million, reflecting a solid foundation for future growth.
    • Growing adoption of advanced therapeutic techniques due to increasing prevalence of bleeding disorders is a major market driver.

    Market Size & Forecast

    2024 Market Size 1250 (USD Million)
    2035 Market Size 2750 (USD Million)
    CAGR (2025 - 2035) 7.43%
    Largest Regional Market Share in 2024 -)

    Major Players

    Apple Inc (US), Microsoft Corp (US), Amazon.com Inc (US), Alphabet Inc (US), Berkshire Hathaway Inc (US), Tesla Inc (US), Meta Platforms Inc (US), Johnson & Johnson (US), Visa Inc (US), Procter & Gamble Co (US)

    Market Trends

    The increasing prevalence of bleeding disorders and surgical procedures in the Middle East and Africa is driving a notable demand for advanced blood coagulants, which are essential for effective patient management and recovery.

    World Health Organization (WHO)

    Blood Coagulants Market Market Drivers

    Rising Geriatric Population

    The aging population in the Middle East and Africa is contributing to the demand for blood coagulants, as older adults are more susceptible to bleeding disorders and related complications. This demographic shift is influencing healthcare priorities and resource allocation within the Global Middle East & Africa Blood Coagulants Market Industry. As the geriatric population continues to grow, healthcare providers are increasingly focusing on preventive measures and effective treatment options. This trend is likely to bolster market growth, aligning with the overall increase in healthcare expenditure and the anticipated market value of 1250 USD Million in 2024.

    Advancements in Biotechnology

    Technological innovations in biotechnology are reshaping the Global Middle East & Africa Blood Coagulants Market Industry. New recombinant factor therapies and bioengineered products are being developed, offering enhanced efficacy and safety profiles compared to traditional treatments. These advancements are likely to attract investment and research efforts, fostering a competitive landscape. As a result, the market is anticipated to grow at a CAGR of 7.43% from 2025 to 2035. The introduction of novel therapies not only improves patient outcomes but also addresses the unmet needs of various bleeding disorders, thereby expanding the overall market.

    Market Trends and Projections

    The Global Middle East & Africa Blood Coagulants Market Industry is witnessing dynamic trends that reflect the evolving landscape of healthcare. Projections indicate a market value of 1250 USD Million in 2024, with an anticipated growth trajectory leading to 2750 USD Million by 2035. The compound annual growth rate (CAGR) of 7.43% from 2025 to 2035 underscores the increasing demand for innovative blood coagulants. This growth is driven by factors such as technological advancements, demographic shifts, and enhanced healthcare policies, which collectively shape the future of the market.

    Growing Awareness and Education

    There is a notable increase in awareness and education regarding bleeding disorders and the importance of blood coagulants in the Global Middle East & Africa Blood Coagulants Market Industry. Educational campaigns and outreach programs are being implemented to inform patients and healthcare professionals about available treatments. This heightened awareness is likely to lead to earlier diagnosis and treatment, ultimately improving patient outcomes. As more individuals seek effective therapies, the market is expected to experience substantial growth, with projections indicating a market value of 2750 USD Million by 2035.

    Government Initiatives and Funding

    Government initiatives aimed at improving healthcare infrastructure and access to treatment are pivotal for the Global Middle East & Africa Blood Coagulants Market Industry. Various countries are implementing policies to enhance the availability of blood coagulants, particularly in underserved regions. Increased funding for healthcare programs and partnerships with pharmaceutical companies are facilitating the development and distribution of essential therapies. This proactive approach is expected to drive market growth, with projections indicating a market value of 1250 USD Million in 2024 and a potential rise to 2750 USD Million by 2035, reflecting the commitment to improving health outcomes.

    Increasing Prevalence of Hemophilia

    The rising incidence of hemophilia and other bleeding disorders in the Global Middle East & Africa Blood Coagulants Market Industry is a critical driver. Hemophilia affects approximately 1 in 5,000 male births, leading to a growing demand for effective coagulant therapies. This trend is particularly evident in regions with limited access to treatment, where patients rely heavily on blood coagulants for managing their conditions. As awareness and diagnosis improve, the market is expected to expand significantly, contributing to the projected market value of 1250 USD Million in 2024 and potentially reaching 2750 USD Million by 2035.

    Market Segment Insights

    Regional Insights

    Key Companies in the Blood Coagulants Market market include

    Industry Developments

    Future Outlook

    Blood Coagulants Market Future Outlook

    The Middle East & Africa Blood Coagulants Market is projected to grow at a 7.43% CAGR from 2024 to 2035, driven by increasing surgical procedures, rising prevalence of bleeding disorders, and advancements in coagulant technologies.

    New opportunities lie in:

    • Develop innovative point-of-care testing devices for rapid coagulant assessment.
    • Expand distribution networks to enhance accessibility in rural healthcare settings.
    • Invest in R&D for next-generation coagulants with improved efficacy and safety profiles.

    By 2035, the market is expected to achieve substantial growth, reflecting enhanced healthcare capabilities and increased demand.

    Market Segmentation

    Key Findings:

    • Hemophilia segment dominates the market with nearly 45.5% share of the MEA market
    • MEA coagulation factor market is projected to reach about USD 141.68 million by 2023
    • MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016
    • UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023

    Intended Audience:

    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors 

    Middle East & Africa Blood Coagulants Market Overview

    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors 

    Figure- MEA blood coagulants market, by Country 2016 (%)

    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors 

    Key Players for Middle East & Africa Blood Coagulants Market

    • Pfizer Inc. (U.S.)
    • Bayer AG (Germany)
    • Novo Nordisk AS (Dernmark)
    • Shire (Republic of Ireland)
    • SOBI (Sweden)
    • Octapharma (Switzerland)
    • CSL Limited (Australia)

    Middle East & Africa Blood Coagulants Market Regional Analysis

    • Hemophilia segment dominates the market with nearly 45.5% share of the MEA market
    • MEA coagulation factor market is projected to reach about USD 141.68 million by 2023
    • MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016
    • UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023

    Report Scope

    Attribute/Metric Details
      Market Size 2030  2.77 Billion
      CAGR (  2023-2030)  6.70%
      Base Year   2022
      Forecast Period   2023-2030
      Historical Data   2021
      Forecast Units   Value (USD Billion)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered  Types and Indication 
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors Pfizer Inc. (U.S.), Bayer AG (Germany), Novo Nordisk AS (Dernmark), Shire (Republic of Ireland), SOBI (Sweden), Octapharma (Switzerland), and CSL Limited (Australia).
      Key Market Opportunities Increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage
      Key Market Drivers Awareness programs for bleeding disorders.

    Market Highlights

    Author

    Kinjoll Dey
    Research Analyst Level I

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    At what CAGR is the Middle East & Africa blood coagulants market projected to grow in the forecast period (2023-2030)?

    Middle East & Africa blood coagulants market is projected to grow at approximately 6.70% CAGR during the assessment period (2023-2030).

    How much is the Middle East & Africa blood coagulants market worth in the future?

    Middle East & Africa blood coagulants market is estimated to reach a valuation of approx. USD 2.77 Billion by the end of 2030.

    What are the major tailwinds pushing the growth of the Middle East & Africa blood coagulants market?

    Rising funding from the private & public organizations, proliferation of healthcare insurance coverage, and awareness programs for bleeding disorders, are major tailwinds pushing the growth of the Middle East & Africa blood coagulants market.

    What are the key growth impeders of the Middle East & Africa blood coagulants market?

    Lack of R&D capabilities and awareness in most of the parts of developing and underdeveloped countries and presence of counterfeit drugs in the regions, are major growth impeder for the Middle East & Africa blood coagulants market.

    Which country holds the largest share in the Middle East & Africa blood coagulants market?

    Saudi Arabia holds the largest share in the Middle East & Africa blood coagulants market.

    Who are the top players in the Middle East & Africa blood coagulants market?

    Pfizer Inc. (U.S.), Novo Nordisk AS (Denmark), Bayer AG (Germany), SOBI (Sweden), Shire (Republic of Ireland), CSL Limited (Australia), and Octapharma (Switzerland), are some of the top players operating in the Middle East & Africa blood coagulants market.

    1. Report Prologue
    2. Research Methodology
      1. Research Process
      2. 10
      3. Primary Research 11
      4. Secondary Research 11
      5. Market Size Estimation 11
      6. Forecast Model 12
    3. Market
      1. Dynamics
      2. Introduction 13
      3. Drivers 14
        1. Rising Funding, Healthcare Insurance
      4. 3.2.1
      5. Bleeding Disorder And Related Conditions Will Push The Demands On Health Systems
      6. (Impact Weightage 75%) 14
      7. Coverage, And Awareness Programs For Bleeding Disorders Are Expected To Boost The
      8. Growth Of The Market (Impact Weightage 25%) 15
      9. Restrains 16
        1. Lack Of R&D Capabilities: (Impact Weightage 45%) 16
        2. Lack Of Awareness (Impact
      10. 3.3.2
      11. Counterfeit Drugs (Impact Weightage 35%) 17
      12. Weightage 20%) 18
    4. Middle East & Africa Blood Coagulants Market
      1. By Type
      2. Introduction 19
      3. Coagulation Factor 22
        1. Recombinant Coagulation Factor 23
        2. Plasma Derived Coagulation
      4. Factor 24
    5. Middle East & Africa Blood Coagulants Market, By Indication
      1. Introduction 25
      2. Haemophilia 27
      3. Surgery
      4. 28
      5. Other Bleeding Disorders 29
    6. Middle East & Africa
    7. Blood Coagulants Market, By Country
      1. Introduction 30
      2. 6.2
      3. Saudi Arabia (KSA) 32
      4. Middle East & Africa Blood Coagulants Market,
      5. By Indication
      6. United Arab Emirates (UAE) 34
      7. Middle East
    8. & Africa Blood Coagulants Market, By Indication
      1. Qatar 36
    9. Middle East & Africa Blood Coagulants Market, By Indication
      1. 6.5
      2. Oman 38
    10. Middle East & Africa Blood Coagulants Market, By Indication
      1. Kuwait 40
      2. Middle East & Africa Blood Coagulants Market,
      3. By Indication
      4. Egypt 42
      5. Middle East & Africa Blood
    11. Coagulants Market, By Indication
      1. Rest Of Middle East & Africa
      2. 44
    12. Middle East & Africa Blood Coagulants Market, By Indication
    13. Company Profiles
      1. Pfizer 46
        1. Company Overview
        2. Financials 46
        3. Products 46
        4. Key Developments 46
      2. 46
      3. 7.1.4
      4. Strategies 46
      5. Bayer AG 47
        1. Company Overview 47
        2. Financials 47
        3. Strategies 47
        4. Key Developments 47
      6. 7.2.3
      7. Products 47
      8. Novo Nordisk AS 48
        1. Company Overview 48
        2. Products 48
        3. Strategies 48
        4. Key Developments 48
      9. 7.3.2
      10. Financials 48
      11. Shire 49
        1. Company Overview
        2. Financials 49
        3. Products 49
      12. 49
      13. 7.4.4
      14. Strategies 49
      15. SOBI 50
        1. Company Overview 50
        2. Financials 50
        3. Products 50
        4. Strategies 50
        5. Key Developments 50
      16. Octapharma 51
        1. Financials 51
        2. Products 51
        3. Strategies 51
        4. Key Developments 51
        5. Company Overview 52
        6. Financials
        7. Products 52
        8. Strategies 52
      17. 7.6.1
      18. Company Overview 51
      19. 7.7
      20. CSL Limited 52
      21. 52
      22. 7.7.5
      23. Key Developments 52
    14. List Of Tables
      1. TABLE
    15. MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET BY TYPE, 2023 TO 2030 (USD MILLION)
      1. 20
    16. MIDDLE EAST & AFRICA COAGULATION FACTOR MARKET BY TYPE,
    17. MIDDLE EAST & AFRICA COAGULATION
      1. FACTOR MARKET BY COUNTRIES, 2023 TO 2030 (USD MILLION) 22
    18. MIDDLE
      1. EAST & AFRICA RECOMBINANT COAGULATION FACTOR MARKET BY COUNTRIES,
      2. TO 2030 (USD MILLION) 23
    19. MIDDLE EAST & AFRICA PLASMA DERIVED
      1. COAGULATION FACTOR MARKET BY COUNTRIES,
    20. MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET BY INDICATION,
    21. MIDDLE EAST & AFRICA BLOOD
      1. COAGULANTS MARKET FOR HAEMOPHILIA BY COUNTRY,
      2. 27
    22. MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET FOR SURGERY
      1. BY COUNTRY,
    23. MIDDLE EAST
      1. & AFRICA BLOOD COAGULANTS MARKET FOR OTHER BLEEDING DISORDERS BY COUNTRY,
    24. MIDDLE EAST & AFRICA
    25. BLOOD COAGULANTS MARKET, BY COUNTRY, 2023 TO 2030 (USD MILLION) 31
      1. TABLE
    26. SAUDI ARABIA BLOOD COAGULANTS MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 32
    27. SAUDI ARABIA COAGULATION FACTOR MARKET BY TYPE, 2023 TO 2030 (USD
      1. MILLION) 32
    28. SAUDI ARABIA BLOOD COAGULANTS MARKET BY INDICATION,
    29. UNITED ARAB EMIRATES BLOOD COAGULANTS
      1. MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 34
    30. UNITED ARAB EMIRATES
      1. COAGULATION FACTOR MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 34
      2. TABLE
    31. UNITED ARAB EMIRATES BLOOD COAGULANTS MARKET BY INDICATION, 2023 TO 2030 (USD
      1. MILLION) 35
    32. QATAR BLOOD COAGULANTS MARKET BY TYPE, 2023 TO 2030
      1. (USD MILLION) 36
    33. QATAR COAGULATION FACTOR MARKET BY TYPE, 2023
      1. TO 2030 (USD MILLION) 36
    34. QATAR BLOOD COAGULANTS MARKET BY INDICATION,
    35. OMAN BLOOD COAGULANTS MARKET BY
      1. TYPE, 2023 TO 2030 (USD MILLION) 38
    36. OMAN COAGULATION FACTOR
      1. MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 38
    37. OMAN BLOOD COAGULANTS
      1. MARKET BY INDICATION, 2023 TO 2030 (USD MILLION) 39
    38. KUWAIT BLOOD
      1. COAGULANTS MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 40
    39. KUWAIT
      1. COAGULATION FACTOR MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 40
      2. TABLE
    40. KUWAIT BLOOD COAGULANTS MARKET BY INDICATION, 2023 TO 2030 (USD MILLION) 41
    41. EGYPT BLOOD COAGULANTS MARKET BY TYPE, 2023 TO 2030 (USD MILLION)
      1. 42
    42. EGYPT COAGULATION FACTOR MARKET BY TYPE, 2023 TO 2030 (USD
      1. MILLION) 42
    43. EGYPT BLOOD COAGULANTS MARKET BY INDICATION, 2023
      1. TO 2030 (USD MILLION) 43
    44. REST OF MEA BLOOD COAGULANTS MARKET
      1. BY TYPE, 2023 TO 2030 (USD MILLION) 44
    45. REST OF MEA COAGULATION
      1. FACTOR MARKET BY TYPE, 2023 TO 2030 (USD MILLION) 44
    46. REST OF
      1. MEA BLOOD COAGULANTS MARKET BY INDICATION, 2023 TO 2030 (USD MILLION) 45
    47. List Of Figures
    48. RESEARCH PROCESS OF MRFR 10
      1. FIGURE
    49. MIDDLE EAST & AFRICA MARKET: FORECAST MODEL 12
    50. MIDDLE
      1. EAST & AFRICA BLOOD COAGULANTS MARKET BY TYPE, 2023 & 2030 (USD MILLION)
      2. 19
    51. MIDDLE EAST & AFRICA COAGULATION FACTOR MARKET BY TYPE,
    52. MIDDLE EAST & AFRICA BLOOD
      1. COAGULANTS MARKET BY INDICATION, 2023 & 2030 (USD MILLION) 25
      2. FIGURE
    53. MIDDLE EAST & AFRICA BLOOD COAGULANTS MARKET, BY COUNTRY, 2023 & 2030
      1. (USD MILLION) 30

    Blood Coagulants Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials